Northwest Biotherapeutics (NWBO) Total Liabilities (2010 - 2026)

Northwest Biotherapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $118.1 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 5.13% year-over-year to $118.1 million; the TTM figure through Mar 2026 stood at $118.1 million (up 5.13% YoY), while the FY2025 annual figure was $128.9 million, up 21.9% from the prior year.
• Total Liabilities for Q1 2026 stood at $118.1 million, down from $128.9 million in the prior quarter.
• The five-year high for Total Liabilities was $151.2 million in Q1 2022, with the low at $64.1 million in Q2 2023.
• The 5-year median for Total Liabilities is $112.3 million (2025), against an average of $104.4 million.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities sank 68.52% in 2022, then jumped 41.09% in 2024.
• Northwest Biotherapeutics' Total Liabilities stood at $136.4 million in 2022, then slumped by 45.06% to $74.9 million in 2023, then surged by 41.09% to $105.7 million in 2024, then grew by 21.9% to $128.9 million in 2025, then slipped by 8.34% to $118.1 million in 2026.
• Business Quant data shows NWBO's Total Liabilities at $118.1 million in Q1 2026, $128.9 million in Q4 2025, and $125.9 million in Q3 2025.